In leading cancer centers clonoSEQ is an essential part of advancing patient care

  • >17,000 unique patients tested
  • 30 of 31 NCCN® Member Institutions currently testing in clinical practice
  • >90 peer-reviewed publications
  • Analytical and clinical validation to meet requirements for FDA clearance
  • >75 ongoing prospective studies in partnership with clinician investigators
  • Broad Medicare coverage across CLL, MM and ALL
  • Pharma partnership in clinical trial studies

For information on ordering clonoSEQ, call us at (888) 552-8988.

clonoSEQ is the only FDA-cleared test to detect and monitor MRD in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, and blood or bone marrow from patients with chronic lymphocytic leukemia.

Are you a blood cancer patient?

Learn about how MRD testing can help you plan for the future and move forward.

Available by prescription use only. For more important info about the FDA-cleared uses of clonoSEQ, including sample types and test limitations visit



    Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

    Larry D. Anderson, Jr., et al.
  • ORAL

    Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

    Saad Zafar Usmani, et al.
  • ORAL

    Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2.

    Philippe Moreau, et al.

    Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.

    Nina Shah, et al.

    Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).

    Benjamin Avi Derman, et al.

clonoSEQ and MRD Assessment in the Management of Lymphoid Malignancies

Allison Jacob, MS
Medical Director, Adaptive Biotechnologies
Friday, June 4, 2021
1:00–1:40 pm EST

Tune into a live presentation from Adaptive Biotechnologies as we discuss the latest advances in next-generation sequencing for minimal residual disease (MRD) detection in lymphoid cancers including CLL, multiple myeloma, and B-ALL.

Sign up to receive event reminders for this live Industry Expert Theater.

    Real-world experience with clonoSEQ

    • What do MRD results mean for an individual patient?
    • How do clonoSEQ results inform clinician and patient decision-making?
    • How is clonoSEQ used in routine clinical practice?

    View cases, videos, patient perspectives and more, which illustrate how clonoSEQ MRD testing is an essential clinical decision-making tool.


    Connect with Medical Affairs

    Request information from a member of our Medical Affairs team.

    View the Summary of Investigator Sponsored Trials

    Request Information

    Adaptive Immune Medicine Platform


    Learn how the platform applies our proprietary technologies, computational biology, software and machine learning to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.

    This page is intended for use by healthcare professionals of the United States.

    clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit